Abstract
IntroductionThe efficacy of adalimumab (ADA) in Crohn's disease (CD) by disease duration has been explored,1 but efficacy and safety of ADA by disease severity have not been investigated. The CHARM2...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
